Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erythropoietin for Alveolar Fluid Clearance in ARDS
NCT05857891Recruiting
- Sponsor
- The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University
- Start
- May 2023
- Primary completion
- Oct 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, double-blind trial of erythropoietin in acute respiratory distress syndrome (ARDS) (2 arms), sponsored by The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University. Primary endpoints: Extravascular Lung Water Index at 72 hours and Pulmonary Vascular Permeability Index at 72 hours. Started May 2023; status: recruiting.
02
Drugs
erythropoietin
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT05857891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05857891.